Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 322,426,944
  • Shares Outstanding, K 6,848,490
  • Annual Sales, $ 64,362 M
  • Annual Income, $ 15,247 M
  • 60-Month Beta 0.32
  • Price/Sales 5.04
  • Price/Cash Flow 14.02
  • Price/Book 7.67
Trade RHHBY with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/04/21
  • Annual Dividend & Yield 0.77 (1.64%)
  • Most Recent Dividend 0.773 on 03/18/21
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.0600 +11.94%
on 05/19/21
48.3800 -2.69%
on 06/16/21
+4.3600 (+10.21%)
since 05/18/21
3-Month
39.9900 +17.73%
on 03/26/21
48.3800 -2.69%
on 06/16/21
+6.1100 (+14.91%)
since 03/18/21
52-Week
39.7200 +18.53%
on 10/30/20
48.3800 -2.69%
on 06/16/21
+2.7000 (+6.08%)
since 06/18/20

Most Recent Stories

More News
Roche SARS-CoV-2 molecular test granted first FDA Emergency Use Authorization for PCR testing of both symptomatic and asymptomatic individuals at the point of care

/PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the SARS-CoV-2 Nucleic acid test for...

RHHBY : 47.0800 (-0.86%)
Worldwide Next Generation Sequencing Industry to 2025 - Competitive Analysis and the Impact of COVID-19

/PRNewswire/ -- The report has been added to offering.

ERRFY : 11.9900 (+19.90%)
ILMN : 456.16 (+0.18%)
QGEN : 47.12 (+0.75%)
RHHBY : 47.0800 (-0.86%)
Biogen (BIIB) Ends Development of Anti-Tau Alzheimer's Drug

Biogen (BIIB) ends development of investigational anti-tau antibody, gosuranemab for treating Alzheimer's disease after the phase II TANGO study showed no benefit to patients.

NVS : 93.01 (-1.21%)
BIIB : 388.44 (+1.28%)
RHHBY : 47.0800 (-0.86%)
AMGN : 238.68 (-0.86%)
Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal

Aprea (APRE) announces that treatment with a combination regimen of its pipeline candidate, eprenetapopt, achieves 37% complete response rate in acute myeloid leukemia patients.

RHHBY : 47.0800 (-0.86%)
ABBV : 113.12 (-1.55%)
APRE : 4.82 (-4.37%)
BNTX : 212.42 (-0.83%)
Glaxo (GSK)/iTeos Therapeutics to Co-Develop Novel Cancer Drug

Glaxo (GSK) signs deal with iTeos Therapeutics to co-develop its investigational cancer candidate known as EOS-448. Glaxo will also study EOS-448 with its other investigational cancer therapies.

GSK : 39.84 (-1.80%)
RHHBY : 47.0800 (-0.86%)
MRK : 76.61 (-0.80%)
ITOS : 25.07 (-5.32%)
Genentech Announces Data at EHA2021 Reinforcing Efficacy of Venclexta Combinations in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia

--- New Phase III MURANO study data suggested certain genetic risk factors may help tailor treatments for patients with previously treated CLL -

RHHBY : 47.0800 (-0.86%)
Merck (MRK) Signs $1.2B Deal With US for COVID-19 Therapeutic

Merck (MRK) is set to supply 1.7 million courses of its oral COVID-19 therapy candidate, molnupiravir, worth $1.2 billion to the U.S. government, following a potential approval or authorization.

JNJ : 161.98 (-1.96%)
RHHBY : 47.0800 (-0.86%)
PFE : 38.81 (-1.70%)
MRK : 76.61 (-0.80%)
argenx (ARGX) to Regain AML Candidate After J&J's Dismissal

argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidate....

JNJ : 161.98 (-1.96%)
RHHBY : 47.0800 (-0.86%)
ABBV : 113.12 (-1.55%)
ARGX : 318.16 (+1.03%)
Biogen (BIIB) Up as FDA Approves Alzheimer'S Drug Aducanumab

FDA approves Biogen's (BIIB) Aduhelm (aducanumab), making it the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.

BIIB : 388.44 (+1.28%)
RHHBY : 47.0800 (-0.86%)
NVS : 93.01 (-1.21%)
AMGN : 238.68 (-0.86%)
Novartis (NVS) Announces Data on Radioligand Therapy at ASCO

Novartis (NVS) posts results from a late-stage study on radioligand therapy at the 2021 ASCO.

AZN : 58.37 (+0.03%)
RHHBY : 47.0800 (-0.86%)
NVS : 93.01 (-1.21%)
BMY : 66.47 (-0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 47.9200
2nd Resistance Point 47.6600
1st Resistance Point 47.3700
Last Price 47.0800
1st Support Level 46.8200
2nd Support Level 46.5600
3rd Support Level 46.2700

See More

52-Week High 48.3800
Last Price 47.0800
Fibonacci 61.8% 45.0719
Fibonacci 50% 44.0500
Fibonacci 38.2% 43.0281
52-Week Low 39.7200

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar